Preferred Label : Vibecotamab;
NCIt synonyms : Anti-CD123/Anti-CD3 Bispecific Antibody XmAb14045;
NCIt definition : An anti-CD123/anti-CD3 bispecific monoclonal antibody, in which most of the naturally-occurring
Fc domain is maintained, with potential immunostimulatory and antineoplastic activities.
Vibecotamab possesses two antigen-recognition and binding sites, one for the CD3 complex,
a group of T-cell surface glycoproteins that complex with the T-cell receptor (TCR),
and one for CD123, a tumor-associated antigen (TAA) overexpressed on the surface of
certain tumor cells. Upon administration of vibecotamab, this bispecific antibody
simultaneously binds to both CD3-expressing T-cells and CD123-expressing cancer cells,
thereby crosslinking CD123-expressing tumor cells and cytotoxic T-lymphocytes (CTLs).
This may result in potent CTL-mediated cell lysis of CD123-expressing tumor cells.
CD123, the interleukin-3 receptor alpha chain, is overexpressed in a variety of hematological
malignancies; its expression is low or absent in normal hematopoietic progenitors
and stem cells. The Fc domain on the antibody prolongs the half-life of the bispecific
antibody and enhances T-cell mediated tumor cell killing through its binding to the
Fc receptors.;
UNII : JD56EJA59S;
CAS number : 2138442-13-2;
Molecule name : XmAb14045;
NCI Metathesaurus CUI : CL507910;
Origin ID : C127120;
UMLS CUI : C5235386;
Semantic type(s)
- chemical_or_drug_has_mechanism_of_action
- concept_is_in_subset
- has_target
